Education
About Us
Working with TipRanks
Follow Us
Q BioMed Inc (QBIO)
OTHER OTC:QBIO
QBIO Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume200.00
Average Volume (3M)N/A
Market Cap
$14.51K
Enterprise Value$4.07M
Total Cash (Recent Filing)$23.17K
Total Debt (Recent Filing)$4.08M
Price to Earnings (P/E)―
Beta86.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding145,094,530
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.16
Price to Sales (P/S)2.52
P/FCF Ratio0.37
Enterprise Value/Market Cap280.83
Enterprise Value/Revenue19.24
Enterprise Value/Gross Profit-403.34
Enterprise Value/Ebitda-1.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
QBIO FAQ
What was Q BioMed Inc’s price range in the past 12 months?
Currently, no data Available
What is Q BioMed Inc’s market cap?
Q BioMed Inc’s market cap is $14.51K.
When is Q BioMed Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Q BioMed Inc’s earnings last quarter?
Currently, no data Available
Is Q BioMed Inc overvalued?
According to Wall Street analysts Q BioMed Inc’s price is currently Overvalued.
Does Q BioMed Inc pay dividends?
Q BioMed Inc does not currently pay dividends.
What is Q BioMed Inc’s EPS estimate?
Q BioMed Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q BioMed Inc have?
Q BioMed Inc has 145,094,530 shares outstanding.
What happened to Q BioMed Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Q BioMed Inc?
Currently, no hedge funds are holding shares in QBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q BioMed Inc
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---